Important Dosing Instructions for MORPHABOND ER

Important Dosing Instructions for MORPHABOND ER1

An easy 1-to-1 conversion from MS Contin®

4 strengths for dosing flexibility and multiple titration options


Tablets not shown at actual size.

Taken orally
every 8 or 12 hours

Instruct patients to
swallow tablets whole

Can be administered
without regard to food

Dosing Considerations for MORPHABOND ER1

  • Reserve MORPHABOND ER for use in patients for whom alternative treatment options (eg, non-opioid analgesics or immediate release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. MORPHABOND ER is not indicated as an as-needed (prn) analgesic
  • Crushing, chewing, or dissolving MORPHABOND ER tablets will result in uncontrolled delivery of morphine and can lead to overdose or death
  • MORPHABOND ER 100-mg tablets, a single dose greater than 60 mg, or a total daily dose greater than 120 mg are only for use in patients in whom tolerance to an opioid of comparable potency has been established
  • Patients who are opioid tolerant are those receiving, for 1 week or longer, at least 60-mg oral morphine per day, 25-mcg transdermal fentanyl per hour, 30-mg oral oxycodone per day, 8-mg oral hydromorphone per day, 25-mg oral oxymorphone per day, 60-mg oral hydrocodone per day, or an equianalgesic dose of another opioid
  • The effect of food upon the systemic bioavailability of MORPHABOND ER has not been systematically evaluated for all strengths. Administration of a single dose of MORPHABOND ER with a standardized high-fat meal resulted in a 33% increase in morphine peak plasma concentration and no change in AUC compared to fasted state

Dosing Considerations for MORPHABOND ER1

MORPHABOND ER should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.

  • Start patients who are opioid naïve or who are not opioid tolerant on 15-mg tablets orally every 8 or 12 hours
    • Use of higher starting doses in patients who are not opioid tolerant may cause fatal respiratory depression
  • Initiate the dosing regimen for each patient individually, taking into account the patient’s severity of pain, response, prior analgesic treatment, and risk factors for addiction, abuse, and misuse
  • Use the lowest effective dose for the shortest duration consistent with individual treatment goals
  • Monitor patients closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy or when adjusting the dose
  • Start with 15 mg every 12 hours and monitor patients for signs of respiratory depression, sedation, and hypotension, and consider using a lower dosage of the concomitant CNS depressant
  • Rapid discontinuation of opioid analgesics in physically dependent patients has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide
  • For patients taking MORPHABOND ER who are physically opioid dependent, initiate the taper by a small enough increment (eg, no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper
  • When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder.

Page navigation - dosing

Why Abuse-Deterrent Formulations

Prescription opioid abuse continues to grow. Abuse-deterrent formulations are just one potential solution to this complex
societal problem

Clinical Abuse Potential Study

Review the data of MORPHABOND ER vs MS Contin® if manipulated and taken intranasally

The MORPHABOND ER Savings Program

Eligible commercially insured patients may pay as little as $10 a month
Please see Eligibility Criteria and Terms and Conditions below.